Further investigations of other downstream mechanisms associated with the tumor suppressor activity of NKAIN2 have the potential to identify more molecular targets for the development of novel therapies, which can be used alone or in combination with Na+/K+-ATPase inhibitors. This evidence concerns the gene NKAIN2 and neoplasm.